OTCPicks.com Stocks to Watch for Tuesday, June 5th

OTCPicks Publisher Newsletter

OTCPicks.com Stocks to Watch for Tuesday, June 5th BWMG, BPAX, EFTI, CBLI, MVIS, IMDS Our Stocks to Watch today include Brownie`s Marine Group Inc. (OTCBB:

BWMG), BioSante Pharmaceuticals Inc. (OTC: BPAX), EarthFirst Technologies Inc. (OTC: EFTI), Cleveland BioLabs Inc. (NASDAQ: CBLI), MicroVision Inc.

(NASDAQ: MVIS) and Imaging Diagnostic Systems Inc. (OTCBB: IMDS).

BROWNIE`S MARINE GROUP (OTC: BWMG.OB) “Up 196.15% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L22&F=T Brownie`s Marine Group, Inc. and its wholly owned subsidiary, Trebor Industries, Inc., d/b/a Brownie`s Third Lung, based in Fort Lauderdale, Florida designs, tests, manufactures and distributes recreational hookah diving, yacht based scuba air compressor and Nitrox Generation Systems, and scuba and water safety products. The Company sells its products both on a wholesale and retail basis and is comprised of three highly specialized dive product groups. The Company is an industry leading manufacturing and distribution company that serves middle-income boat owners, higher income yacht owners, recreational divers, military operators and public safety personnel.

BWMG News:

May 25 – Brownie`s Marine Group, Inc. Enters Booming Recreation Retail Sector With Grand Opening of Brownie`s Dive & Paddle Adventure Center Brownie`s Marine Group, Inc. (OTCBB: BWMG), a leading developer, manufacturer and distributor of highly specialized dive and safety products, today announced the grand opening of its Marine Adventure Center, Brownie`s Dive & Paddle in Boca Raton, FL. (176-B Glades Road in Boca Raton) The grand opening will take place on May 30th and will feature an abundance of grand opening specials, prizes and brand new, never before seen diving-related amazements! Brownie`s, which was founded in 1969 has evolved into a vertically integrated designer, manufacturer and retailer of numerous innovative and proprietary products including:

* Brownie`s Third Lung * SCUBA tank fill and NITROX MAKER systems for yachts * World-class hookah diving systems for boats and kayaks, and * Stand-Up Paddle Boards for outdoor enthusiast of all types Brownie`s has selected Boca Raton as a key location to introduce this one-of-a-kind concept store. Florida is the epicenter of the adventure-dive universe and industry pioneer, Robert Carmichael, founder and CEO of Brownie`s has now taken this concept from vision to execution. Mr.

Carmichael will be on-site, overseeing operations during the initial launch phase of the store.

Brownie`s Dive and Paddle STORE features:

* “Tank-Valet” where Brownie staff greets customers curbside with a portable Nitrox and Air fill manifold powered by a patented computer controlled and automated 4-bank cascade and twin compressor system.

* Nitrox, the preferred breathing gas for sport diving is produced onsite by Brownie`s State of the Art and Patented “NitroxMaker” eliminating the need to purchase, or manage pure oxygen; a distinct operational and consumer advantage.

* The finest brands in SUP (stand-up paddle boards): Suplove, Hovie, Riviera, Kings, Boga, Bote, Fanatic, ULI inflatables, and MHL-Precision Paddleboards are showcased on a space saving overhead swivel-rack that was also designed and fabricated by Brownie`s.

* Halcyon Diving System`s, the consensus leader in perfect balanced and streamlined “Made in the USA” SCUBA buoyancy compensators, dive vehicles, lighting systems, and extreme exploration essentials are showcased alongside a complete selection of SCUBAPRO, UWATEC, and SUB GEAR, traditional scuba products.

* Spearfishing Specialties, which Brownie`s has partnered with, to bring in a complete selection of the “RHINO” brand products, also made in the USA.

Go-Pro, Contour and Sony Camera systems and underwater lights and housings are not only offered for sale, but include full dry and wet instruction by our in-house professional staff.

Mr Carmichael enthused, “To see the final product of Brownie`s Dive and Paddle super store concept is just amazing for me and for the dive community as a whole. I don`t believe anything like this exists and I know Brownie`s will become THE destination location for dive enthusiasts near and far.” He continued, “The unique concept combined with quality training, demonstrations, as well as dive boat training operations are expected to be the foundation to building a sustainable customer base around this store model.” BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX) “Up 18.13% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L3&F=T BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante`s lead products include LibiGel (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook). Additional information is available online at www.biosantepharma.com.

BPAX News:

June 4 – BioSante Pharmaceuticals, Inc. to Present at Jefferies Global Healthcare Conference BioSante Pharmaceuticals, Inc. (OTC: BPAX) announced that Stephen M. Simes, BioSantes president & CEO will present a corporate update at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 11:00 am EDT.

Mr. Simes will provide an overview of BioSante, as well as an update on the LibiGel (testosterone gel) Phase III clinical development program, and a review of published results using BioSantes GVAX Cancer Immunotherapies in combination with ipilimumab (Ipi; Yervoy; BMS).

EARTHFIRST TECHNOLOGIES INCORPORATED (OTC: EFTI) “Up 400.00% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L92&F=T EarthFirst Technologies, Incorporated, through its subsidiaries, engages in the development and commercialization of technologies for the production of alternative fuel sources; and the destruction and/or remediation of liquid and solid waste, as well as in the supply of electrical contracting services in the United States and internationally. The company, through World Environmental Solutions Company, Inc., focuses on the commercialization of its Solid Waste Remediation Plant in Mobile, Alabama. This plant processes rubber tires, extracting carbon, and other raw materials for resale and allows raw materials from those waste products to be recycled and reused. EarthFirst Technologies, through Electric Machinery Enterprises, Inc., provides electrical contracting and subcontracting services in the construction of commercial, residential, and municipal projects primarily located in Florida and the Caribbean. The company, through SolarDiesel Corporation, engages in the development, marketing, and distribution of biofuels produced from palm oil, soy, and rapeseed in the United States, Latin America, the Caribbean, and Europe.

EarthFirst Technologies also provides technologies for the treatment of liquid waste products that involves the use of high temperature plasma, through which the liquid waste products are passed. The company was founded in 1997 and is headquartered in Tampa, Florida. On June 13, 2008, EarthFirst Technologies Incorporated, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S.

Bankruptcy Court for the Middle District of Florida, Tampa.

EFTI News:

No recent news for EarthFirst Technologies, Inc. (OTC: EFTI).

CLEVELAND BIOLABS INCORPORATED (NASDAQ: CBLI) “Up 62.99% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L23&F=T Cleveland BioLabs, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for cancer treatment, and protection of normal tissues from radiation and other acute stresses. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which are small molecules intended to destroy tumor cells by simultaneously targeting two regulators of apoptosis. The company has a strategic research partnership with Roswell Park Cancer Institute to develop its anticancer and radioprotectant drug candidates; a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds; and a strategic alliance with The Cleveland Clinic Foundation (CCF). It also has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences; the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.; and CCF to evaluate its radioprotective drug candidates and their effects on intracellular and extracellular signaling pathways. The company was founded in 2003 and is headquartered in Buffalo, New York.

CBLI News:

June 4 – Cleveland BioLabs Reports Strong Survival Results Which Met the Primary Endpoint of Its GLP Efficacy Study With Radiation Countermeasure CBLB502 Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in 179 non-human primates (NHPs) conducted under Good Laboratory Practice (GLP) with elements of Good Clinical Practice (GCP), as required by the U.S. Food and Drug Administration`s (FDA) Animal Rule. The study demonstrated with a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals, the study`s primary endpoint.

Animals in the study received a 70% lethal dose of total body irradiation (TBI) followed by a single injection of a range of doses of CBLB502 or a placebo, in each case, 25 hours after irradiation. In addition to determination of 60-day survival, the study measured multiple pharmacodynamic parameters which the Company believes are essential for animal-to-human dose conversion.

A minimal efficacious dose of CBLB502 was determined and doses above the minimal efficacious dose formed a plateau at approximately 75% survival, compared to 27.5% survival in the placebo treated group. These results demonstrated with a high degree of statistical significance (p < 0.0001 for the trend up to the 40 ug/kg dose and p = 0.0021 for the trend up to the 10 ug/kg dose) that a single administration of CBLB502 given 25 hours after TBI led to a nearly three-fold increase in overall survival in the subject animals.

Ann Hards, Ph.D., Executive Vice President of Regulatory Affairs and Quality Assurance, stated, “We are very pleased with the compelling survival data reported in this study. In addition to demonstrating CBLB502`s effect on survival, we believe this study supports our methodology for dose conversion between animals and humans. We plan on using the findings from this trial as a basis for finalizing our remaining development steps with the FDA and, ultimately, submitting our Biologic License Application.” Yakov Kogan, Ph.D., MBA, interim Chief Executive Officer, commented: “I congratulate our team on the rigorous execution of this study. To our knowledge, this trial is the first ever GLP/GCP compliant, randomized, blinded study done with any radiation countermeasure. CBLB502 continues to exceed our expectations and we are as committed as ever to moving this program forward.” MICROVISION INCORPORATED (NASDAQ: MVIS) “Up 11.04% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L18&F=T MicroVision provides the PicoP display technology platform designed to enable next-generation display and imaging products for consumer devices, vehicle displays and wearable displays. The company`s PicoP projection display technology uses highly efficient laser light sources which can create vivid images with high contrast and brightness. MicroVision is an independently recognized leader in the development of intellectual property. MicroVision has been recognized by IEEE as a top 20 IP portfolio among all global electronics companies, and the top U.S. Company in the rankings. MicroVisions intellectual property portfolio has also been recognized by the Patent Board, in association with the Wall Street Journal as a top 50 IP portfolio among all global industrial companies. The Patent Board has developed more than 50 indicators that track global patent activity relating to companies` innovation, technology, and science strengths. MicroVisions intellectual property portfolio is further recognized by having been added to the Ocean Tomo 300 Patent Index.

MVIS News:

May 31 – MicroVision Receives Purchase Orders in Excess of $4M from Pioneer Corporation for PicoP Gen2 Technology MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it has received purchase orders from Pioneer Corporation valued in excess of $4 million.

The purchase orders cover key components, including MEMS and electronics, which are part of the companys patented next generation HD PicoP display technology based on direct green lasers (PicoP Gen2) that Pioneer is integrating into its Cyber Navi car navigation system.

Pioneer is MicroVisions first customer under its Image by PicoP ingredient brand business model whereby it sells components and receives license fees and royalties for its patented PicoP display technology.

Pioneers Cyber Navi head-up display (HUD) is the first commercial product based on MicroVisions PicoP Gen2 display technology.

MicroVision has already begun shipping components to Pioneer for its aftermarket HUD product that is expected to be available in Japan in July.

The Cyber Navi is the worlds first HUD to project augmented reality information in front of the windscreen and the worlds first onboard HUD to use lasers. The product was designed to offer drivers a new way to experiencing data on the road.

Pioneer will combine the MEMS and electronics it receives from MicroVision with red, blue and direct green lasers from Pioneers laser suppliers to create optical engines based on MicroVisions patented PicoP reference design. The PicoP display technology embedded in the HUD delivers bright, clear, full color images viewable in daylight in a small form factor with low power requirements.

IMAGING DIAGNOSTIC SYSTEMS (OTCBB: IMDS) “Up 33.33% on Monday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N61&L4&F=T Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and shows the process of angiogenesis, which usually accompanies tumor growth. CTLM system has received international certifications and licenses from the European CE mark, CMDCAS Canadian Health screening, China SFDA, India, UL, and ISO 13485. The Company is seeking FDA approval through the Premarket approval process.

IMDS News:

May 22 – Imaging Diagnostic`s Non-Invasive CTLM Laser Breast Imaging Device Will Soon Be Available to Women in Kuwait Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging, announced that it has signed a distribution agreement with Mareen Group to market and sell its Computed Tomography Laser Mammography (CTLM) System in Kuwait.

“Mareen Group is honored to present the CTLM to the women of Kuwait. We are eager to support the imaging needs of patients through this dignified and innovative laser breast imaging modality,” commented Ahmad Abdulrahman, General Manager of Mareen Group.

Mareen Group is a Medical & Pharmaceutical distribution company well established and based in Kuwait. They have been in operation since 1998, proudly providing various medical and healthcare institutions within Kuwait and the surrounding areas with advanced medical equipment and pharmaceuticals from across the globe. The philosophy of Mareen Group has always been to build close ties with their customers by supporting their every need with prompt professional service and support.

Imaging Diagnostic`s CEO, Linda Grable, states, “IDSI is delighted to assign Mareen Group, a well established medical company in Kuwait, as our new distributor. The women in Kuwait will hopefully benefit from CTLM`s unique and discrete breast imaging process to aid in the diagnosis and management of breast abnormalities. We are enthusiastic to work with Mareen Group to make the CTLM, a non-invasive alternative, accessible to women in Kuwait.” OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N61&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N61&L=8&F=T.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.

Related posts:

1. OTCPicks.com Daily Market Movers Digest Midday Report for Monday, June 4th
2. OTCPicks.com Daily Market Movers Digest Midday Report for Monday, June 4th
3. OTCPicks.com Daily Market Movers Digest Midday Report for Friday, June 1st
4. OTCPicks.com Stocks to Watch for Monday, June 4th
5. OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, May 23rd